西亚试剂:Celgene's $2.6B deal for Crohn's drug pays off with promisi

发布时间：2026-02-17

Celgene's $2.6B deal for Crohn's drug pays off with promising PhII

Celgene ($CELG) bet big on the little-known Irish biotech Nogra Pharma when it partnered on a mid-stage drug for Crohn's disease. And today Celgene spelled out the reasons why it gambled $710 million upfront on a Phase II drug, highlighting data that support a clear case that the therapy can help spur clinical remission in a broad group of patients.

"Clinical remission was achieved by significantly greater proportions of patients receiving Mongersen (GED-0301) 40 (55.0%) and 160 mg/day (65.1%) compared with placebo (9.5%; p<0.0001 for both)," Celgene noted in an abstract. "No significant difference in clinical remission was seen for 10 mg/day (12.2%) vs. placebo. The rate of clinical response was significantly greater among patients receiving 10 (36.6%), 40 (57.5%) or 160 mg/day (72.1%) of Mongersen vs. placebo (16.7%; p=0.039, p=0.0001 and p<0.0001, respectively). The rates of adverse events (AEs) and serious AEs (SAEs) were similar across groups."

Mongersen is an oral antisense oligonucleotide that is designed to zero in on Smad7 near the end of the colon, where it can incite an inflammatory response. Celgene had already seen these results when it bought in for the upfront plus $1.9 billion in development and sales milestones. For analysts, who had to adjust their expectations for Celgene after the deal, the numbers helped underscore the potential for this drug.

"Overall, data from the ~160 patient trial (40 per arm) is at the high end of our expectations and perhaps roughly in-line with consensus Street expectations," notes ISI's Mark Schoenebaum. "Thus, my best guess at this point is that the stock will rise modestly today."

"GED-0301, a first-in-class oral antisense therapy, has the potential to change the treatment landscape for Crohn's disease," said Scott Smith, who runs Celgene's inflammation and immunology group. "Celgene is excited to pursue the clinical development program for this novel therapy in phase III trials in the near future."

Celgene is no stranger to the world of biotech deals. The company has one of the most active partnering groups in the industry, and there's a big interest in diversifying the company's product portfolio outside of cancer.

For now, Celgene appears ready to deliver on that promise. Mongersen is slated to start Phase III before the end of this year.

• 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询   
• 相关产品如汞乙酸汞氯化汞氧化汞碘化汞硫酸汞硝酸汞溴化汞硝酸亚汞氯化亚汞乙酸苯汞碘化汞钾硫氰酸汞氯化氨基汞三氯生三氯氧磷三氯乙烯水合氯醛三氯化磷三氯化钌三氯化钛三氯化铱三氯化铑三氯硫磷三氯乙烷三氯甲烷三氯卡班TCC1,3,5-三氯苯1,2,4-三氯苯1,2,3-三氯苯无水氯化铝三氯乙酸酐三氯乙酸钠碘甲烷二碘甲烷三碘甲烷 三氟碘甲烷硫酸二甲酯氯磺酸苯硫酚苯硫酚钠3-氨基苯硫酚2,6-二氯苯硫酚2,4-二氯苯硫酚2,5-二氯苯硫酚2-甲氧基苯硫酚2-氯乙醇氯甲基甲醚 等均有销售.欢迎订购

 

上一篇：三星芯片工厂发生二氧化碳泄漏事故
下一篇：四氯化钛制法工艺